ArticleFrontiers in endocrinology2026
Maternal serum uric acid before 24 weeks of gestation and subsequent gestational diabetes mellitus: a multicentre retrospective cohort study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This multicentre retrospective cohort study examined whether maternal serum uric acid measured before 24 weeks of gestation was associated with subsequent gestational diabetes mellitus (GDM), with hypertensive disorders of pregnancy (HDP) assessed as a related cardiometabolic outcome. Methods: We included 5,614 pregnancies from three hospitals in China. For each pregnancy, the earliest eligible uric acid measurement before 24 weeks of gestation was retained. Uric acid was analysed in quartiles and per 10 μmol/L increase. Modified Poisson regression with robust variance estimated relative risks (RRs), restricted cubic splines assessed dose-response patterns, and sensitivity analyses examined the stability of the findings. Results: GDM occurred in 1,187 pregnancies (21.1%) and HDP in 275 pregnancies (4.9%). Compared with Q1, Q4 was associated with higher risk of GDM (adjusted RR, 1.54; 95% CI, 1.34 to 1.77) and HDP (adjusted RR, 1.89; 95% CI, 1.33 to 2.67). Each 10 μmol/L increase in uric acid was associated with GDM (adjusted RR, 1.03; 95% CI, 1.02 to 1.04) and HDP (adjusted RR, 1.04; 95% CI, 1.02 to 1.06). Spline analyses showed modest evidence of nonlinearity for GDM but not for HDP. Discussion: Maternal serum uric acid measured before 24 weeks of gestation was associated with subsequent GDM, with a related association observed for HDP. Uric acid may complement established maternal risk factors but should not be interpreted as a standalone screening test.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.